Attainment of normal lipid levels among high cardiovascular risk patients: Pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada

European Journal of Internal Medicine

Volumn 24, Issue 7, 2013, Pages 656-663

  Ambegaonkar, Baishali M ^a   Bash, Lori D ^a   Chirovsky, Diana R ^b   Jameson, Kevin ^c   Grant, Susan ^d   Nocea, Gonzalo ^e   Pettersson, Billie ^a   Sazonov, Vasilisa ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Merck Sharp & Dohme Limited   (United Kingdom)

^d Merck Canada   (Canada)

^e Medical affairs Merck sharp and Dohme ltd   (Spain)

Author keywords

Cardiovascular disease; Diabetes; High density lipoprotein cholesterol; Lipid modifying therapy; Low density lipoprotein cholesterol; Statins; Triglycerides

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CANADA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIABETES MELLITUS; ELECTRONIC MEDICAL RECORD; FEMALE; FRAMINGHAM RISK SCORE; GOAL ATTAINMENT; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; RISK MANAGEMENT; SMOKING; SPAIN; SWEDEN; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

CARDIOVASCULAR DISEASE; DIABETES; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; LIPID MODIFYING THERAPY; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; STATINS; TRIGLYCERIDES;

ADULT; AGED; CANADA; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; OBSERVATIONAL STUDY AS TOPIC; PREVALENCE; RISK FACTORS; SPAIN; SWEDEN; TRIGLYCERIDES;

EID: 84884288889     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2013.07.005     Document Type: Article

References (50)

1. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr., L.T. Clark, and D.B. Hunninghake Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
2. I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, and R. Cifkova European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 28 2007 2375 2414
3. R. McPherson, J. Frohlich, G. Fodor, J. Genest, and Canadian Cardiovascular S Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease Can J Cardiol 22 2006 913 927
4. J.C. LaRosa, J. He, and S. Vupputuri Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials JAMA 282 1999 2340 2346
5. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, and T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 1977 707 714
6. S. Lewington, G. Whitlock, R. Clarke, P. Sherliker, J. Emberson, and J. Halsey Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 370 2007 1829 1839
7. A. Morrison, and J.E. Hokanson The independent relationship between triglycerides and coronary heart disease Vasc Health Risk Manag 5 2009 89 95
8. J.E. Hokanson, and M.A. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219
9. M. Abdel-Maksoud, V. Sazonov, S.W. Gutkin, and J.E. Hokanson Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes J Cardiovasc Pharmacol 51 2008 331 351
10. I.M. Singh, M.H. Shishehbor, and B.J. Ansell High-density lipoprotein as a therapeutic target: a systematic review JAMA 298 2007 786 798
11. J.W. Jukema, C.W. Chiang, J. Ferrieres, R.D. Santos, J. Verdejo, and D.D. Waters Lipid goals among patients with diabetes or metabolic syndrome: lipid treatment assessment project (L-TAP) 2 Curr Med Res Opin 26 2010 2589 2597
12. H. Phatak, C. Wentworth, V. Sazonov, and T. Burke Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice Atherosclerosis 202 2009 225 233
13. E. Van Ganse, T. Souchet, L. Laforest, P. Moulin, M. Bertrand, and P. Le Jeunne Ineffectiveness of lipid-lowering therapy in primary care Br J Clin Pharmacol 59 2005 456 463
14. T. Walley, and A. Mantgani The UK general practice research database Lancet 350 1997 1097 1099
15. V. Sazonov, J. Beetsch, H. Phatak, C. Wentworth, and M. Evans Association between dyslipidemia and vascular events in patients treated with statins: report from the UK general practice research database Atherosclerosis 208 2010 210 216
16. B. Pettersson, B. Ambegaonkar, V. Sazonov, M. Martinell, J. Stalhammar, and P. Wandell Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA) BMC Public Health 10 2010 737
17. K.M. Anderson, P.M. Odell, P.W. Wilson, and W.B. Kannel Cardiovascular disease risk profiles Am Heart J 121 1991 293 298
18. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
19. J.V. Lozano, V. Pallares, L. Cea-Calvo, J.L. Llisterri, C. Fernandez-Perez, and J.C. Marti-Canales Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study Curr Med Res Opin 24 2008 659 670
20. H. Ghandehari, S. Kamal-Bahl, and N.D. Wong Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004 Am Heart J 156 2008 112 119
21. E. Van Ganse, L. Laforest, T. Burke, H. Phatak, and T. Souchet Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study Clin Ther 29 2007 1671 1681
22. J. Ferrieres, E. Berard, O. Crisan, and V. Bongard Residual dyslipidaemia after statin treatment in France: prevalence and risk distribution Arch Cardiovasc Dis 103 2010 302 309
23. G.A. Nichols, B.M. Ambegaonkar, V. Sazonov, and J.B. Brown Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy Am J Cardiol 104 2009 1689 1694
24. R.S. Birjmohun, B.A. Hutten, J.J. Kastelein, and E.S. Stroes Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials J Am Coll Cardiol 45 2005 185 197
25. J.R. Guyton, and H.E. Bays Safety considerations with niacin therapy Am J Cardiol 99 2007 22C 31C
26. H.E. Bays, A. Shah, J. Lin, C. McCrary Sisk, J.F. Paolini, and D. Maccubbin Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome J Clin Lipidol 4 2010 515 521
27. D. Maccubbin, M.J. Koren, M. Davidson, D. Gavish, R.C. Pasternak, and G. Macdonell Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease Am J Cardiol 104 2009 74 81
28. P.L. Canner, K.G. Berge, N.K. Wenger, J. Stamler, L. Friedman, and R.J. Prineas Fifteen year mortality in coronary drug project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
29. L.A. Carlson, and G. Rosenhamer Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid Acta Med Scand 223 1988 405 418
30. B.G. Brown, X.Q. Zhao, A. Chait, L.D. Fisher, M.C. Cheung, and J.S. Morse Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
31. W.E. Boden, J.L. Probstfield, T. Anderson, B.R. Chaitman, P. Desvignes-Nickens, and K. Koprowicz Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
32. AIM-HIGH Investigators The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol rationale and study design. The atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides: impact on global health outcomes (AIM-HIGH) Am Heart J 161 3 Mar. 2011 471 477 (Epub 2011 Feb 2)
33. S.J. Nicholls The AIM-HIGH (atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides: impact on global health outcomes) trial: to believe or not to believe? J Am Coll Cardiol 59 2012 2065 2067
34. Roche Roche provides update on phase III study of dalcetrapib Available at: http://www.roche.com/media/media-releases/med-cor-2012-05-07.htm 2012 [Last accessed]
35. A.J. Hooper, and J.R. Burnett Dalcetrapib, a cholesteryl ester transfer protein modulator Expert Opin Investig Drugs 21 9 Sep. 2012 1427 1432 (Epub 2012 Jun 24)
36. M.H. Frick, O. Elo, K. Haapa, O.P. Heinonen, P. Heinsalmi, and P. Helo Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245
37. V. Manninen, L. Tenkanen, P. Koskinen, J.K. Huttunen, M. Manttari, and O.P. Heinonen Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment Circulation 85 1992 37 45
38. S.J. Robins, D. Collins, J.T. Wittes, V. Papademetriou, P.C. Deedwania, and E.J. Schaefer Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591
39. A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, and M.R. Taskinen Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
40. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the bezafibrate infarction prevention (BIP) study Circulation 102 2000 21 27
41. T. Meade, R. Zuhrie, C. Cook, and J. Cooper Bezafibrate in men with lower extremity arterial disease: randomised controlled trial BMJ 325 2002 1139
42. H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse III, L.A. Leiter, and P. Linz Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
43. W.S. Harris n - 3 fatty acids and serum lipoproteins: human studies Am J Clin Nutr 65 1997 1645S 1654S
44. M.H. Davidson, K.C. Maki, T.A. Pearson, R.C. Pasternak, P.C. Deedwania, and J.M. McKenney Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP writing group recommendations Am J Cardiol 96 2005 556 563
45. A.A. Alsheikh-Ali, J.L. Lin, P. Abourjaily, D. Ahearn, J.T. Kuvin, and R.H. Karas Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents Am J Cardiol 98 2006 1231 1233
46. F.D. de Rojas, T. De Frutos, A. Ponte, J.M. Chacon, and G.C. Vitale Coronary heart disease and dyslipidemia: a cross-sectional evaluation of prevalence, current treatment, and clinical control in a large cohort of Spanish high-risk patients: the PRINCEPS study Prev Cardiol 12 2009 65 71
47. D.D. Waters, C. Brotons, C.W. Chiang, J. Ferrieres, J. Foody, and J.W. Jukema Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals Circulation 120 2009 28 34
48. J. Ferrieres, E.T. Gousse, C. Fabry, and M.P. Hermans Assessment of lipid-lowering treatment in France - the CEPHEUS study Arch Cardiovasc Dis 101 2008 557 563
49. F.J. Garcia Ruiz, A. Marin Ibanez, F. Perez-Jimenez, X. Pinto, G. Nocea, and C. Ahumada Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY study Pharmacoeconomics 22 2004 1 12
50. E. Van Ganse, L. Laforest, E. Alemao, G. Davies, S. Gutkin, and D. Yin Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study Curr Med Res Opin 21 2005 1389 1399